Cargando…

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

Detalles Bibliográficos
Autores principales:	Shakir, Rebecca, Gilmour-Hamilton, Catriona, Bakin, Craig, Gent, Isabelle, Holloway, Adam, Meeson, Alison, Ramroth, Johanna, Ntentas, Georgios, Cutter, David, Peters, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Early Stages
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621476/ http://dx.doi.org/10.1097/01.HS9.0000890656.40235.fb

Ejemplares similares

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
por: Gallamini, Andrea, et al.
Publicado: (2022)

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
por: Taszner, Michal, et al.
Publicado: (2022)

P014: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
por: Sousa, Rita Costa E., et al.
Publicado: (2022)

Remote multidisciplinary heart team meetings in immersive virtual reality: a first experience during the COVID-19 pandemic
por: Sadeghi, Amir H, et al.
Publicado: (2021)

P012: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
por: Pierdomenico, Francesca, et al.
Publicado: (2022)

P018: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
por: Biasoli, Irene, et al.
Publicado: (2022)

P019: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
por: Dorokhina, Elena, et al.
Publicado: (2022)

P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose
por: Almeida, Cátia, et al.
Publicado: (2022)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
por: Laura, Korin, et al.
Publicado: (2022)

P016: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
por: Dragičević, Ida Hude, et al.
Publicado: (2022)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022)

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
por: Jain, Hasmukh, et al.
Publicado: (2022)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
por: Hutchings, Martin, et al.
Publicado: (2022)

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
por: Diepstra, Arjan, et al.
Publicado: (2022)

P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
por: Dorokhina, Elena, et al.
Publicado: (2022)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
por: Rusconi, Chiara, et al.
Publicado: (2022)

P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
por: Viviani, Simonetta, et al.
Publicado: (2022)

42P Radiation induced pneumonitis in the era of the COVID-19 pandemic: Artificial intelligence for differential diagnosis
por: Ramella, S., et al.
Publicado: (2021)

44P Inter-reader variability of lung parenchymal observations on chest CT among COVID-19 RT-PCR negative lung cancer patients treated with chemo-radiation: Potential pitfalls of pulmonary findings in different readers with various experience levels
por: Jajodia, A., et al.
Publicado: (2021)

43P Incidentally discovered suspicious lung lesions in hospitalized patients during the COVID-19 pandemic in Georgia
por: Abuladze, M., et al.
Publicado: (2021)

Impact of the Covid-19 pandemic on a District General Hospital EBUS service
por: Wright, Matthew, et al.
Publicado: (2021)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
por: Santarsieri, Anna, et al.
Publicado: (2022)

P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
por: Parsons, Susan K., et al.
Publicado: (2022)

Increased proportion of patients diagnosed with lung cancer as a result of an acute hospital admission during the COVID-19 pandemic, and associated inequalities
por: Taylor, Rebecca
Publicado: (2023)

Impact of COVID 19 on EBUS services
por: Dugdale, Isobel, et al.
Publicado: (2023)

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma
por: Cutter, David J., et al.
Publicado: (2021)

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
por: Geurts, Yvonne M.G., et al.
Publicado: (2022)

Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection
por: Ntentas, Georgios, et al.
Publicado: (2022)

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
por: Houlihan, Orla A., et al.
Publicado: (2022)

Shared Decision Making in Cardiovascular Patient Care to Address Cardiovascular Disease Disparities
por: Turkson‐Ocran, Ruth‐Alma N., et al.
Publicado: (2021)

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
por: Ntentas, Georgios, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dorlor7o1jmmlskjhi2h6ku65b